References
1. Li FP, Fraumeni JF, Mulvihill JJ, et al. A Cancer Family Syndrome in Twenty-four Kindreds. Cancer Res . 1988;48(18):5358-5362.
2. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations.Oncogene . 2001;20(34):4621-4628. doi:10.1038/sj.onc.1204621
3. Candanedo-González FA, Alvarado-Cabrero I, Gamboa-Domínguez A, et al. Sporadic type composite pheochromocytoma with neuroblastoma: Clinicomorphologic, DNA content, and ret gene analysis. Endocr Pathol . 2001;12(3):343-350. doi:10.1385/EP:12:3:343
4. Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell . 2017;170(6):1062-1078. doi:10.1016/j.cell.2017.08.028
5. Bougeard G, Renaux-Petel M, Flaman jean michel, et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol Off J Am Soc Clin Oncol . 2015;33. doi:10.1200/JCO.2014.59.5728
6. Tang YJ, Yu TT, Ma J, Zhou Y, Xu M, Gao YJ. Composite Adrenocortical Carcinoma and Neuroblastoma in an Infant With a TP53 Germline Mutation: A Case Report and Literature Review. J Pediatr Hematol Oncol . 2019;41(5):399-401. doi:10.1097/MPH.0000000000001205
7. Pivnick EK, Furman WL, Velagaleti GV, Jenkins JJ, Chase NA, Ribeiro RC. Simultaneous adrenocortical carcinoma and ganglioneuroblastoma in a child with Turner syndrome and germline p53 mutation. J Med Genet . 1998;35(4):328-332. doi:10.1136/jmg.35.4.328
8. Rossbach HC, Baschinsky D, Wynn T, Obzut D, Sutcliffe M, Tebbi C. Composite adrenal anaplastic neuroblastoma and virilizing adrenocortical tumor with germline TP53 R248W mutation. Pediatr Blood Cancer . 2008;50(3):681-683. doi:https://doi.org/10.1002/pbc.21219
9. Seidinger AL, Fortes FP, Mastellaro MJ, et al. Occurrence of Neuroblastoma among TP53 p.R337H Carriers. PLOS ONE . 2015;10(10):e0140356. doi:10.1371/journal.pone.0140356
10. Courtney R, Ranganathan S. Simultaneous Adrenocortical Carcinoma and Neuroblastoma in an Infant With a Novel Germline p53 Mutation. J Pediatr Hematol Oncol . 2015;37(3):215-218. doi:10.1097/MPH.0000000000000281
11. Muller PAJ, Vousden KH. Mutant p53 in Cancer: New Functions and Therapeutic Opportunities. Cancer Cell . 2014;25(3):304-317. doi:10.1016/j.ccr.2014.01.021
12. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors | Nature Chemical Biology. Accessed March 21, 2021. https://www.nature.com/articles/nchembio.546
13. Zerdoumi Y, Aury‐Landas J, Bonaïti‐Pellié C, et al. Drastic Effect of Germline TP53 Missense Mutations in Li–Fraumeni Patients. Hum Mutat . 2013;34(3):453-461. doi:https://doi.org/10.1002/humu.22254
14. Schlegelberger B, Kreipe H, Lehmann U, et al. A child with Li–Fraumeni syndrome: Modes to inactivate the second allele of TP53 in three different malignancies. Pediatr Blood Cancer . 2015;62(8):1481-1484. doi:https://doi.org/10.1002/pbc.25486
15. Bougeard G, Sesboüé R, Baert-Desurmont S, et al. Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families.J Med Genet . 2008;45(8):535-538. doi:10.1136/jmg.2008.057570
16. Jung H, Bae GE, Kim HM, Kim HS. Clinicopathological and Molecular Differences Between Gastric-type Mucinous Carcinoma and Usual-type Endocervical Adenocarcinoma of the Uterine Cervix. Cancer Genomics Proteomics . 2020;17(5):627-641. doi:10.21873/cgp.20219